ATE490969T1 - Modifizierte transferrin-fusionsproteine - Google Patents
Modifizierte transferrin-fusionsproteineInfo
- Publication number
- ATE490969T1 ATE490969T1 AT02757486T AT02757486T ATE490969T1 AT E490969 T1 ATE490969 T1 AT E490969T1 AT 02757486 T AT02757486 T AT 02757486T AT 02757486 T AT02757486 T AT 02757486T AT E490969 T1 ATE490969 T1 AT E490969T1
- Authority
- AT
- Austria
- Prior art keywords
- fusion proteins
- transferrin fusion
- modified transferrin
- transferrin
- modified
- Prior art date
Links
- 102000037865 fusion proteins Human genes 0.000 title abstract 3
- 108020001507 fusion proteins Proteins 0.000 title abstract 3
- XNSAINXGIQZQOO-SRVKXCTJSA-N protirelin Chemical class NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H]1NC(=O)CC1)CC1=CN=CN1 XNSAINXGIQZQOO-SRVKXCTJSA-N 0.000 title 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 abstract 2
- 102000004338 Transferrin Human genes 0.000 abstract 2
- 108090000901 Transferrin Proteins 0.000 abstract 2
- 210000002966 serum Anatomy 0.000 abstract 2
- 239000012581 transferrin Substances 0.000 abstract 2
- 102000007238 Transferrin Receptors Human genes 0.000 abstract 1
- 108010033576 Transferrin Receptors Proteins 0.000 abstract 1
- 230000013595 glycosylation Effects 0.000 abstract 1
- 238000006206 glycosylation reaction Methods 0.000 abstract 1
- 229910052742 iron Inorganic materials 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/79—Transferrins, e.g. lactoferrins, ovotransferrins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/644—Transferrin, e.g. a lactoferrin or ovotransferrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Emergency Medicine (AREA)
- Neurosurgery (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US31574501P | 2001-08-30 | 2001-08-30 | |
| US33405901P | 2001-11-30 | 2001-11-30 | |
| PCT/US2002/027637 WO2003020746A1 (en) | 2001-08-30 | 2002-08-30 | Modified transferrin fusion proteins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE490969T1 true ATE490969T1 (de) | 2010-12-15 |
Family
ID=26980047
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT02757486T ATE490969T1 (de) | 2001-08-30 | 2002-08-30 | Modifizierte transferrin-fusionsproteine |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20040023334A1 (de) |
| EP (1) | EP1427750B1 (de) |
| JP (2) | JP2005508623A (de) |
| KR (1) | KR20040059490A (de) |
| CN (1) | CN1628126A (de) |
| AT (1) | ATE490969T1 (de) |
| AU (1) | AU2002323501C1 (de) |
| BR (1) | BR0212256A (de) |
| CA (1) | CA2457520A1 (de) |
| DE (1) | DE60238541D1 (de) |
| DK (1) | DK1427750T3 (de) |
| IL (1) | IL160289A0 (de) |
| MX (1) | MXPA04001804A (de) |
| NZ (1) | NZ531207A (de) |
| RU (1) | RU2004109222A (de) |
| WO (1) | WO2003020746A1 (de) |
| ZA (1) | ZA200401079B (de) |
Families Citing this family (139)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7176278B2 (en) * | 2001-08-30 | 2007-02-13 | Biorexis Technology, Inc. | Modified transferrin fusion proteins |
| CN1628126A (zh) * | 2001-08-30 | 2005-06-15 | 比奥雷克西斯药物公司 | 经修饰的运铁蛋白融合蛋白 |
| US8129504B2 (en) | 2001-08-30 | 2012-03-06 | Biorexis Technology, Inc. | Oral delivery of modified transferrin fusion proteins |
| US20030226155A1 (en) * | 2001-08-30 | 2003-12-04 | Biorexis Pharmaceutical Corporation | Modified transferrin-antibody fusion proteins |
| ATE452650T1 (de) * | 2002-08-30 | 2010-01-15 | Biorexis Pharmaceutical Corp | Transferrin-fusionsproteinbibliotheken |
| CN102268094A (zh) * | 2002-08-30 | 2011-12-07 | 比奥雷克西斯药物公司 | 被修饰的转铁蛋白抗体的融合蛋白 |
| US20060105387A1 (en) * | 2002-08-30 | 2006-05-18 | Prior Christopher P | Transferrin fusion proteins libraries |
| US7592306B2 (en) * | 2002-12-10 | 2009-09-22 | Agennix, Inc. | Lactoferrin as an agent in the prevention of organ transplant rejection and graft-versus-host-disease |
| US7772188B2 (en) | 2003-01-28 | 2010-08-10 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
| US20070060512A1 (en) * | 2003-03-04 | 2007-03-15 | Homayoun Sadeghi | Dipeptidyl-peptidase protected protein |
| US7379700B2 (en) * | 2003-05-06 | 2008-05-27 | Canon Kabushiki Kaisha | Image reading apparatus with rotatable internal and external guides |
| AU2004289170B2 (en) * | 2003-06-06 | 2009-12-17 | Agennix Incorporated | Lactoferrin as an adjuvant in cancer vaccines |
| US20060205037A1 (en) * | 2003-08-28 | 2006-09-14 | Homayoun Sadeghi | Modified transferrin fusion proteins |
| JP2007512001A (ja) * | 2003-08-28 | 2007-05-17 | バイオレクシス ファーマシューティカル コーポレイション | Ｅｐｏミメティックペプチドおよび融合タンパク質 |
| CN1938333A (zh) * | 2003-12-03 | 2007-03-28 | 达尔塔生物技术有限公司 | 白介素－11融合蛋白 |
| US7906140B2 (en) * | 2004-06-17 | 2011-03-15 | Virun, Inc. | Compositions for mucosal delivery of agents |
| WO2006047744A2 (en) * | 2004-10-26 | 2006-05-04 | Agennix Incorporated | Compositions of lactoferrin related peptides and uses thereof |
| US20090275481A1 (en) * | 2005-06-17 | 2009-11-05 | Pfizer, Inc. | Anchored Transferrin Fusion Protein Libraries |
| JP4976412B2 (ja) | 2005-12-01 | 2012-07-18 | ベー・エル・アー・ハー・エム・エス・ゲーエムベーハー | エンドセリン、エンドセリンアゴニスト及びアドレノメジュリンアンタゴニストによる危篤患者の診断及び治療のための方法 |
| DK2046826T3 (da) * | 2006-07-24 | 2011-10-24 | Biorexis Pharmaceutical Corp | Exendin-fusionsproteiner |
| KR100744419B1 (ko) | 2006-08-03 | 2007-07-30 | 동부일렉트로닉스 주식회사 | 반도체 소자 및 반도체 소자의 제조 방법 |
| EP2114999A2 (de) | 2006-12-12 | 2009-11-11 | Biorexis Pharmaceutical Corporation | Transferrin-fusionsproteinbibliotheken |
| EP2594583A1 (de) | 2007-08-08 | 2013-05-22 | Novozymes Biopharma DK A/S | Transferrinvarianten und Konjugate |
| PT2277890E (pt) * | 2008-05-23 | 2016-03-31 | Daiichi Sankyo Co Ltd | Péptido capaz de prolongar o semi-período de vida do péptido de interesse no plasma |
| ES2915692T3 (es) | 2008-08-13 | 2022-06-24 | California Inst Of Techn | Nanopartículas portadoras y composiciones, métodos y sistemas relacionados |
| US20110294988A1 (en) | 2009-02-06 | 2011-12-01 | Novozymes Bio Pharma DK A/S | Purification Process |
| EP2216341A1 (de) | 2009-02-10 | 2010-08-11 | Novozymes Biopharma UK Limited | Transferrinvarianten und -konjugate |
| US9644197B2 (en) * | 2010-06-04 | 2017-05-09 | Sk Chemicals Co., Ltd. | Fusion protein having factor VII activity |
| KR101853405B1 (ko) * | 2010-10-20 | 2018-05-02 | 주식회사 티움바이오 | 인자 ｉｘ 활성을 갖는 융합 단백질 |
| CN103443125B (zh) | 2010-11-30 | 2019-05-03 | 霍夫曼-拉罗奇有限公司 | 低亲和力血脑屏障受体抗体及其用途 |
| US20120148488A1 (en) * | 2010-12-10 | 2012-06-14 | California Institute Of Technology | Targeting Kidney Mesangium With Nanoparticles of Defined Diameter |
| US9290562B2 (en) | 2011-08-17 | 2016-03-22 | The Regents Of The University Of Colorado | Transferrin-tumstatin fusion protein and methods for producing and using the same |
| BR112014011670B1 (pt) | 2011-11-16 | 2021-05-25 | Adrenomed Ag | anticorpo anti-adrenomedulina (adm) ou fragmento de anticorpo anti-adm ou um arcabouço de proteína não-igg anti-adm que se liga à adrenomedulina e formulação farmacêutica |
| HRP20190122T1 (hr) | 2011-11-16 | 2019-03-08 | Adrenomed Ag | Protutijelo protiv adrenomedulina (adm) ili fragment protutijela protiv adm ili okosnica ne-ig protiv adm, namijenjeni reguliranju ravnoteže tekućina kod pacijenta s kroničnom ili akutnom bolešću |
| PL3553084T3 (pl) | 2011-11-16 | 2023-04-17 | Adrenomed Ag | Przeciwciało przeciwko adrenomedulinie (adm) lub fragment przeciwciała przeciwko adm lub szkielet przeciwko adm inny niż ig do profilaktyki lub zmniejszania zaburzenia czynności narządu lub niewydolności narządu u pacjenta cierpiącego na przewlekłą lub ostrą chorobę lub ostry stan |
| HRP20191771T1 (hr) | 2011-11-16 | 2019-12-27 | Adrenomed Ag | Anti-adrenomedulin (adm) antitijelo ili fragment anti-adm antitijela ili anti-adm non-ig skela za uporabu u terapiji akutne bolesti ili akutnog stanja pacijenta za stabiliziranje cirkulacije |
| US9140696B2 (en) | 2011-11-16 | 2015-09-22 | Adrenomed Ag | Anti-adrenomedullin (ADM) antibody or anti-ADM antibody fragment or anti-ADM non-IG scaffold for reducing the risk of mortality in a patient having a chronic or acute disease or acute condition |
| ES2494190T3 (es) | 2011-11-16 | 2014-09-15 | Adrenomed Ag | Anticuerpo anti-adrenomedulina (ADM) o fragmento de anticuerpo anti-ADM o andamiaje proteico sin Ig anti-ADM para reducir el riesgo de mortalidad en un paciente que padece una enfermedad crónica o aguda o un estado agudo |
| CN103308673B (zh) | 2012-03-08 | 2017-05-31 | 思芬构技术有限公司 | 用于预测雌性对象中发生心血管事件的风险的方法 |
| CN103308670B (zh) | 2012-03-08 | 2017-06-09 | 思芬构技术有限公司 | 用于预测对象患糖尿病和/或代谢综合征的风险的方法 |
| CN103308689B (zh) | 2012-03-08 | 2017-04-12 | 思芬构技术有限公司 | 用于预测雌性对象中患上癌症的风险或诊断癌症的方法 |
| HK1212448A1 (en) | 2012-09-07 | 2016-06-10 | The Governors Of The University Of Alberta | Methods and compositions for diagnosis of inflammatory liver disease |
| ES2810001T3 (es) | 2012-10-02 | 2021-03-08 | Sphingotec Gmbh | Un método para diagnosticar o monitorizar la función renal |
| CA2893639C (en) * | 2012-12-04 | 2021-01-05 | F. Hoffmann-La Roche Ag | Biomarkers in the selection of therapy of heart failure |
| RU2677895C2 (ru) | 2013-01-08 | 2019-01-22 | Сфинготек Гмбх | Уровни гормона роста натощак в качестве прогностического маркера сердечно-сосудистого риска |
| CA2901404A1 (en) * | 2013-02-15 | 2014-08-21 | The Royal Institution For The Advancement Of Learning/Mcgill University | Modified ingap peptides for treating diabetes |
| MY170528A (en) * | 2013-02-18 | 2019-08-09 | Vegenics Pty Ltd | Vegfr-3 ligand binding molecules and uses thereof |
| US9468681B2 (en) | 2013-03-01 | 2016-10-18 | California Institute Of Technology | Targeted nanoparticles |
| US9132097B2 (en) | 2013-03-01 | 2015-09-15 | California Institute Of Technology | Nanoparticles stabilized with nitrophenylboronic acid compositions |
| US20160039877A1 (en) | 2013-03-15 | 2016-02-11 | Shenzhen Hightide Biopharmaceutical, Ltd. | Compositions and methods of using islet neogenesis peptides and analogs thereof |
| WO2014147153A1 (en) | 2013-03-20 | 2014-09-25 | Sphingotec Gmbh | Adrenomedullin to guide therapy of blood pressure decline |
| US10208125B2 (en) | 2013-07-15 | 2019-02-19 | University of Pittsburgh—of the Commonwealth System of Higher Education | Anti-mucin 1 binding agents and uses thereof |
| EP3002589A1 (de) | 2014-10-01 | 2016-04-06 | sphingotec GmbH | Verfahren zur stratifizierung einer frau zur hormonersatztherapie |
| JP6743022B2 (ja) | 2014-12-24 | 2020-08-19 | ネクシミューン インコーポレイテッド | 免疫療法のためのナノ粒子組成物及び方法 |
| ES3075629T3 (en) | 2015-04-24 | 2026-08-06 | Sphingotec Gmbh | A method for predicting the risk of incidence of chronic kidney disease |
| EP3317323B1 (de) | 2015-07-01 | 2021-05-26 | California Institute of Technology | Kationische schleimsäurepolymerbasierte abgabesysteme |
| EP3371311B1 (de) | 2015-11-06 | 2021-07-21 | Orionis Biosciences BV | Bifunktionale chimäre proteine und verwendungen davon |
| EP3377080B1 (de) | 2015-11-19 | 2024-02-14 | Asclepix Therapeutics, LLC | Peptide mit anti-angiogenen, anti-lymphangiogenen und anti-ödematösen eigenschaften und nanopartikelformulierungen |
| RU2614141C1 (ru) * | 2015-12-28 | 2017-03-23 | федеральное государственное бюджетное образовательное учреждение высшего образования "Тюменский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ФГБОУ ВО Тюменский ГМУ Минздрава России) | Способ прогнозирования парафарингиального абсцесса при остром паратонзиллите |
| CN109071632B (zh) | 2016-02-05 | 2022-12-30 | 奥里尼斯生物科学私人有限公司 | 靶向性治疗剂及其用途 |
| US11248057B2 (en) | 2016-03-07 | 2022-02-15 | Vib Vzw | CD20 binding single domain antibodies |
| IL262472B2 (en) | 2016-04-21 | 2024-12-01 | 4TEEN4 Pharmaceuticals GmbH | Dpp3 inhibitors for use in treating diseases related to necrosis |
| EP3455245A2 (de) | 2016-05-13 | 2019-03-20 | Orionis Biosciences NV | Therapeutisches targeting von nichtzellulären strukturen |
| WO2017194783A1 (en) | 2016-05-13 | 2017-11-16 | Orionis Biosciences Nv | Targeted mutant interferon-beta and uses thereof |
| US11390661B2 (en) | 2016-06-27 | 2022-07-19 | Aicuris Anti-Infective Cures Gmbh | HCMV entry inhibitors |
| CN109716136B (zh) | 2016-07-08 | 2023-09-22 | 斯弗因高泰克有限公司 | 肾上腺髓质素用于评估急性心力衰竭患者的充血 |
| WO2018067646A1 (en) | 2016-10-04 | 2018-04-12 | Asclepix Therapeutics, Llc | Compounds and methods for activating tie2 signaling |
| EP3309550A1 (de) | 2016-10-12 | 2018-04-18 | sphingotec GmbH | Verfahren zum nachweis von apolipoprotein e4 |
| CN110114368B (zh) | 2016-10-24 | 2024-08-02 | 奥睿尼斯生物科学私人有限公司 | 靶向突变干扰素-γ及其用途 |
| EP3339324A1 (de) | 2016-12-22 | 2018-06-27 | sphingotec GmbH | Anti-adrenomedullin (adm)-antikörper oder anti-adm antikörperfragment oder anti-adm-nicht-ig-gerüst zur verwendung in einer intervention und therapie von verstopfung bei einem darauf angewiesenen patienten |
| KR20190120174A (ko) | 2016-12-16 | 2019-10-23 | 아드레노메드 아게 | 울혈의 중재 및 치료가 필요한 환자에서 울혈의 중재 및 치료에 사용하기 위한 항-아드레노메둘린 (ADM) 항체 또는 항-ADM 항체 단편 또는 항-ADM 비-Ig 스캐폴드 |
| EP3576765B1 (de) | 2017-02-06 | 2025-07-16 | Orionis Biosciences, Inc. | Zielgerichtetes manipuliertes interferon und verwendungen davon |
| KR102642385B1 (ko) | 2017-02-06 | 2024-03-04 | 오리오니스 바이오사이언시스 엔브이 | 표적화된 키메라 단백질 및 이의 용도 |
| CA3050601A1 (en) | 2017-02-07 | 2018-08-16 | Vib Vzm | Immune-cell targeted bispecific chimeric proteins and uses thereof |
| RU2019144031A (ru) | 2017-05-30 | 2021-06-30 | Сфинготек Гмбх | Способ диагностики или мониторинга функции почек или диагностики дисфункции почек |
| WO2019006348A1 (en) * | 2017-06-30 | 2019-01-03 | Western University Of Health Sciences | IX-TRANSFERRIN FACTOR FUSION PROTEINS |
| US11674959B2 (en) | 2017-08-03 | 2023-06-13 | The Johns Hopkins University | Methods for identifying and preparing pharmaceutical agents for activating Tie1 and/or Tie2 receptors |
| US20220227854A1 (en) | 2017-09-25 | 2022-07-21 | Adrenomed Ag | Anti-adrenomedullin (adm) binder for use in therapy or prevention of symptoms of illness |
| WO2019075056A1 (en) | 2017-10-10 | 2019-04-18 | The Johns Hopkins University | BIODEGRADABLE BIOMIMETIC PARTICLES |
| MX2020004072A (es) | 2017-10-18 | 2020-07-28 | Adrenomed Ag | Monitoreo de terapia bajo tratamiento con un aglutinante anti-adrenomodulina (adm). |
| RU2020115377A (ru) | 2017-10-24 | 2021-11-25 | Сфинготек Гмбх | Селенопротеин p для прогнозирования первого сердечно-сосудистого явления |
| KR102835427B1 (ko) | 2017-10-25 | 2025-07-21 | 4틴4 파마슈티컬스 게엠베하 | 특이적 dpp3-에피토프에 대하여 지시되고 이에 결합하는 dpp3 결합제 및 산화적 스트레스와 연관되는 질환 / 급성 병태의 예방 또는 치료에서의 그의 용도 |
| US12655186B2 (en) | 2018-01-26 | 2026-06-16 | Orionis Biosciences, Inc. | Chimeric protein comprising anti-XCR1 antibody and modified interferon alpha 2 |
| CA3090406A1 (en) | 2018-02-05 | 2019-08-08 | Orionis Biosciences, Inc. | Fibroblast binding agents and use thereof |
| KR102717599B1 (ko) | 2018-02-08 | 2024-10-14 | 스핑고텍 게엠베하 | 치매의 진단 및/또는 예측을 위한 아드레노메둘린 (adm) 및 치매의 요법 또는 예방에 사용하기 위한 항-아드레노메둘린 결합제 |
| EP3569614A1 (de) | 2018-05-18 | 2019-11-20 | Julius-Maximilians-Universität Würzburg | Verbindungen und verfahren zur immobilisierung von myostatin-inhibitoren auf der extrazellulären matrix durch transglutaminase |
| US20190381188A1 (en) | 2018-06-13 | 2019-12-19 | California Institute Of Technology | Nanoparticles For Crossing The Blood Brain Barrier And Methods Of Treatment Using The Same |
| EP3586865A1 (de) | 2018-06-21 | 2020-01-01 | Charité - Universitätsmedizin Berlin | Ergänzende anaphylatoxinbindemittel und deren verwendung in der behandlung einer person mit okularer wunde und/oder fibrose |
| EP3890773A4 (de) | 2018-11-08 | 2022-11-09 | Orionis Biosciences, Inc. | Modulation von dendritischen zelllinien |
| CA3124020A1 (en) | 2018-12-20 | 2020-06-25 | Sphingotec Gmbh | Selenoprotein p in heart failure |
| US20220211798A1 (en) | 2018-12-21 | 2022-07-07 | 4TEEN4 Pharmaceuticals GmbH | Therapy guidance and/or therapy monitoring for a treatment with angiotensin-receptor-agonist and/or a precursor thereof |
| US11254736B2 (en) | 2019-02-15 | 2022-02-22 | Integral Molecular, Inc. | Antibodies comprising a common light chain and uses thereof |
| CN119708241A (zh) | 2019-02-15 | 2025-03-28 | 因特格尔莫来库乐有限公司 | 密封蛋白6抗体及其用途 |
| WO2020198665A1 (en) | 2019-03-28 | 2020-10-01 | Orionis Biosciences, Inc. | Fibroblast activation protein binding agents and use thereof |
| US20220291234A1 (en) | 2019-08-15 | 2022-09-15 | Sphingotec Gmbh | A method for diagnosing or monitoring kidney function or diagnosing kidney dysfunction in pediatric patients |
| WO2021038078A1 (en) | 2019-08-30 | 2021-03-04 | 4TEEN4 Pharmaceuticals GmbH | Therapy guidance and/or therapy monitoring for treatment of shock |
| KR102613552B1 (ko) | 2019-09-20 | 2023-12-14 | 엠브릭스 주식회사 | 목적 단백질의 수용성 및 열안정성을 증가시키기 위한 태그 단백질 및 이를 포함하는 융합 단백질 |
| EP3871689A1 (de) | 2020-02-26 | 2021-09-01 | sphingotec GmbH | Anti-adm-antikörper, die an den freien n-terminus binden, für einen beschleunigten übergang von adm-gly zu bio-adm bei patienten mit einem adm-gly/bio-adm-verhältnis über einem schwellenwert und kombination mit vitamin c |
| CN115244401A (zh) | 2020-02-27 | 2022-10-25 | 4Teen4制药有限公司 | 用于在休克患者中进行nt-adm抗体的治疗指导、监测和分层的dpp3 |
| CN115244081A (zh) | 2020-02-27 | 2022-10-25 | 艾德里诺医药公司 | 用于治疗休克患者的抗肾上腺髓质素(adm)结合剂 |
| CA3168978A1 (en) | 2020-02-27 | 2021-09-02 | Andreas Bergmann | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in therapy or prevention of shock |
| US20210285949A1 (en) | 2020-03-16 | 2021-09-16 | Sphingotec Gmbh | Pro-adrenomedullin or fragment thereof in patients infected with corona virus and treatments with binder against adrenomedullin |
| EP3922993A1 (de) | 2020-06-12 | 2021-12-15 | 4TEEN4 Pharmaceuticals GmbH | Dpp3 bei patienten, die mit coronavirus infiziert sind |
| US20230213519A1 (en) | 2020-03-16 | 2023-07-06 | 4TEEN4 Pharmaceuticals GmbH | Dpp3 in patients infected with coronavirus |
| GB202004514D0 (en) | 2020-03-27 | 2020-05-13 | Inst De Medicina Molecular Joaeo Lobo Antunes | Treatment of Immunosuppressive Cancer |
| CA3195512A1 (en) | 2020-10-14 | 2022-04-21 | Vahe Bedian | Compositions and methods for treatment of thyroid eye disease |
| EP4023218A1 (de) | 2020-12-02 | 2022-07-06 | S-Form Pharma | Kombinationstherapie für patienten mit akuter und/oder anhaltender dyspnoe |
| US11180534B1 (en) * | 2021-06-04 | 2021-11-23 | Morehouse School Of Medicine | Compositions and methods for treating SARS-CoV-2 infections |
| US20240272178A1 (en) | 2021-06-18 | 2024-08-15 | Sphingotec Gmbh | A method for predicting sepsis and septic shock |
| WO2023275099A1 (en) | 2021-06-29 | 2023-01-05 | Berysol Gmbh | Composite biomarker for the identification of selenium deficiency in a bodily fluid |
| JP2024531151A (ja) | 2021-08-10 | 2024-08-29 | ビリジアン セラピューティクス， インコーポレイテッド | 甲状腺眼疾患の処置のための組成物、用量および方法 |
| CN119072492A (zh) | 2022-03-15 | 2024-12-03 | 艾德里诺医药公司 | 抗肾上腺髓质素（adm）抗体或抗adm抗体片段的稳定水性制剂 |
| US20250304677A1 (en) | 2022-07-04 | 2025-10-02 | Vib Vzw | Blood-Cerebrospinal Fluid Barrier Crossing Antibodies |
| IL318667A (en) | 2022-07-29 | 2025-03-01 | Adrenomed Ag | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in therapy or prevention of shock |
| US20260028423A1 (en) | 2022-07-29 | 2026-01-29 | 4TEEN4 Pharmaceuticals GmbH | Prediction of an increase of dpp3 in a patient with septic shock |
| AU2023356326A1 (en) | 2022-10-06 | 2025-03-27 | Bicara Therapeutics Inc. | Multispecific proteins and related methods |
| CN120282987A (zh) | 2022-11-30 | 2025-07-08 | 因特格尔莫来库乐有限公司 | 包括双特异性型式的针对紧密连接蛋白6的抗体 |
| US20260201067A1 (en) | 2022-12-15 | 2026-07-16 | 4TEEN4 Pharmaceuticals GmbH | Dpp3 inhibitor for improvement of pulmonary function in critically ill patients |
| EP4680966A1 (de) | 2023-03-17 | 2026-01-21 | PAM Theragnostics GmbH | Verfahren zur bestimmung der peptidylglycin-alpha-amidierenden monooxygenase (pam) und deren verwendung für diagnostische zwecke |
| JP2026513177A (ja) | 2023-03-29 | 2026-04-23 | ４ティーン４ ファーマシューティカルズ ゲゼルシャフト ミット ベシュレンクテル ハフツング | 血圧低下を有する重症患者における心筋保護及び心筋傷害の予防のためのｄｐｐ３阻害剤 |
| JP2026519919A (ja) | 2023-04-03 | 2026-06-19 | ブイアイビー ブイゼットダブリュ | 血液脳関門通過抗体 |
| CN122003247A (zh) | 2023-07-07 | 2026-05-08 | 维里迪安治疗公司 | 治疗活动性和慢性甲状腺眼病的方法 |
| KR20260044219A (ko) | 2023-07-21 | 2026-04-01 | 매로우 테라퓨틱스, 인크. | 조혈 세포 표적화 접합체 및 관련 방법 |
| CN121889677A (zh) | 2023-09-25 | 2026-04-17 | 思芬构技术有限公司 | 用于肾移植患者中移植物功能降低的早期诊断、早期预测、监测或严重程度预测的方法 |
| AU2024373680A1 (en) | 2023-11-03 | 2026-06-18 | Neuvasq Biotechnologies Sa | Wnt7 signaling agonists |
| AU2024408268A1 (en) | 2023-12-17 | 2026-07-09 | Viridian Therapeutics, Inc. | Compositions, doses, and methods for treatment of thyroid eye disease |
| WO2025151502A1 (en) | 2024-01-09 | 2025-07-17 | Viridian Therapeutics, Inc. | Modified antibodies |
| WO2025151496A1 (en) | 2024-01-09 | 2025-07-17 | Viridian Therapeutics, Inc. | Compositions and methods for treatment of thyroid eye disease |
| WO2025151492A1 (en) | 2024-01-09 | 2025-07-17 | Viridian Therapeutics, Inc. | Compositions and methods for treatment of thyroid eye disease |
| US20250375499A1 (en) | 2024-01-26 | 2025-12-11 | Flagship Pioneering Innovations Vii, Llc | Immunoreceptor inhibitory proteins and related methods |
| WO2025229075A1 (en) | 2024-05-03 | 2025-11-06 | Sphingotec Gmbh | A method for the specific determination of proenkephalin fragment 119-159 |
| TW202613158A (zh) | 2024-05-16 | 2026-04-01 | 美商旗艦先鋒創新有限責任（Ｖｉｉ）公司 | 免疫受體抑制蛋白及相關方法 |
| WO2025245111A1 (en) | 2024-05-22 | 2025-11-27 | Flagship Pioneering Innovations Vii, Llc | Immunoreceptor targeting proteins and related methods |
| WO2025248139A1 (en) | 2024-05-31 | 2025-12-04 | 4TEEN4 Pharmaceuticals GmbH | Use of adrenomedullin or fragments thereof in the treatment of a patient in need thereof |
| EP4675277A1 (de) | 2024-07-05 | 2026-01-07 | Predemtec AG | Verfahren zur diagnose von morbus alzheimer oder zur bestimmung des risikos des leidens an morbus alzheimer |
| US20260015407A1 (en) | 2024-07-15 | 2026-01-15 | Flagship Pioneering Innovations Vii, Llc | Immunomodulatory fusion proteins and related methods |
| WO2026046978A1 (en) | 2024-08-26 | 2026-03-05 | Pam Theragnostics Gmbh | Anti-adm antibodies, anti-adm antibody fragment or anti-adm non-ig scaffold for therapy or prevention of immune effector cell therapy side effects |
| WO2026046968A1 (en) | 2024-08-26 | 2026-03-05 | 4TEEN4 Pharmaceuticals GmbH | Dpp3 binders for the treatment of endothelial dysfunction |
| WO2026122747A2 (en) | 2024-12-05 | 2026-06-11 | Flagship Pioneering Innovations Vii, Llc | Novel immunomodulatory proteins and related methods |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2001A (en) * | 1841-03-12 | Sawmill | ||
| US4289689A (en) * | 1980-03-14 | 1981-09-15 | Hoffmann-La Roche Inc. | Preparation of homogeneous human fibroblast interferon |
| WO1982002715A1 (fr) * | 1981-02-04 | 1982-08-19 | Sugano Haruo | Gene d'interferon (beta)humain |
| US4816449A (en) * | 1984-08-09 | 1989-03-28 | Immunetech Pharmaceuticals | Immunotherapeutic anti-inflammatory peptide agents |
| US5026651A (en) * | 1985-04-25 | 1991-06-25 | Board Of Regents, The University Of Texas System | Methods and compositions for the production of human transferrin |
| US5262177A (en) * | 1986-02-07 | 1993-11-16 | Oncogen | Recombinant viruses encoding the human melanoma-associated antigen |
| US5260203A (en) * | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
| US5091513A (en) * | 1987-05-21 | 1992-02-25 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| NZ226414A (en) | 1987-10-02 | 1992-07-28 | Genentech Inc | Cd4 peptide adhesion variants and their preparation and use |
| US5116964A (en) * | 1989-02-23 | 1992-05-26 | Genentech, Inc. | Hybrid immunoglobulins |
| US5571691A (en) * | 1989-05-05 | 1996-11-05 | Baylor College Of Medicine | Production of recombinant lactoferrin and lactoferrin polypeptides using CDNA sequences in various organisms |
| FR2650598B1 (fr) | 1989-08-03 | 1994-06-03 | Rhone Poulenc Sante | Derives de l'albumine a fonction therapeutique |
| US5977307A (en) * | 1989-09-07 | 1999-11-02 | Alkermes, Inc. | Transferrin receptor specific ligand-neuropharmaceutical agent fusion proteins |
| US5672683A (en) * | 1989-09-07 | 1997-09-30 | Alkermes, Inc. | Transferrin neuropharmaceutical agent fusion protein |
| US6066469A (en) * | 1990-03-08 | 2000-05-23 | Ferro Dynamics, Inc. | Cloning, expression, and uses of human lactoferrin |
| US5723286A (en) * | 1990-06-20 | 1998-03-03 | Affymax Technologies N.V. | Peptide library and screening systems |
| US5986067A (en) | 1991-02-08 | 1999-11-16 | The University Of Vermont And State Agricultural College | Recombinant transferrins, transferrin half-molecules and mutants thereof |
| US5656272A (en) * | 1991-03-18 | 1997-08-12 | New York University Medical Center | Methods of treating TNF-α-mediated Crohn's disease using chimeric anti-TNF antibodies |
| CA2110404A1 (en) * | 1991-05-31 | 1992-12-10 | Christina Teng | Human lactoferrin |
| FR2686899B1 (fr) * | 1992-01-31 | 1995-09-01 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant. |
| ZA932568B (en) * | 1992-04-24 | 1993-11-12 | Baylor College Midecine A Non | Production of recombinant human lactoferrin |
| EP0599303A3 (de) * | 1992-11-27 | 1998-07-29 | Takeda Chemical Industries, Ltd. | Peptide-Konjugate |
| US5464933A (en) * | 1993-06-07 | 1995-11-07 | Duke University | Synthetic peptide inhibitors of HIV transmission |
| US5843882A (en) * | 1995-04-27 | 1998-12-01 | The United States Of America As Represented By The Department Of Health And Human Services | Antiviral proteins and peptides |
| US5817789A (en) * | 1995-06-06 | 1998-10-06 | Transkaryotic Therapies, Inc. | Chimeric proteins for use in transport of a selected substance into cells |
| US5849293A (en) * | 1996-01-11 | 1998-12-15 | Cornell Research Foundation, Inc. | Use of human transferrin in controlling insulin levels |
| US6458924B2 (en) * | 1996-08-30 | 2002-10-01 | Novo Nordisk A/S | Derivatives of GLP-1 analogs |
| US7235627B2 (en) * | 1996-08-30 | 2007-06-26 | Novo Nordisk A/S | Derivatives of GLP-1 analogs |
| US6258782B1 (en) * | 1998-05-20 | 2001-07-10 | Trimeris, Inc. | Hybrid polypeptides with enhanced pharmacokinetic properties |
| PT1180121E (pt) * | 1999-05-17 | 2004-03-31 | Conjuchem Inc | Peptidos insulinotropicos de longa duracao |
| US6380362B1 (en) * | 1999-12-23 | 2002-04-30 | Genesis Research & Development Corporation Ltd. | Polynucleotides, polypeptides expressed by the polynucleotides and methods for their use |
| US6420346B1 (en) * | 2000-02-07 | 2002-07-16 | Rappaport Family Institute For Research In The Medical Sciences | Polynucleotides encoding MIP-1α, MCP-1, MIP-1β, Rantes and TNF-α, and methods for treating rheumatoid arthritis |
| US7176278B2 (en) * | 2001-08-30 | 2007-02-13 | Biorexis Technology, Inc. | Modified transferrin fusion proteins |
| CN1628126A (zh) * | 2001-08-30 | 2005-06-15 | 比奥雷克西斯药物公司 | 经修饰的运铁蛋白融合蛋白 |
| US20060105387A1 (en) * | 2002-08-30 | 2006-05-18 | Prior Christopher P | Transferrin fusion proteins libraries |
| CN102268094A (zh) * | 2002-08-30 | 2011-12-07 | 比奥雷克西斯药物公司 | 被修饰的转铁蛋白抗体的融合蛋白 |
| US20060205037A1 (en) * | 2003-08-28 | 2006-09-14 | Homayoun Sadeghi | Modified transferrin fusion proteins |
-
2002
- 2002-08-30 CN CNA028216377A patent/CN1628126A/zh active Pending
- 2002-08-30 RU RU2004109222/13A patent/RU2004109222A/ru not_active Application Discontinuation
- 2002-08-30 BR BR0212256-1A patent/BR0212256A/pt not_active IP Right Cessation
- 2002-08-30 EP EP02757486A patent/EP1427750B1/de not_active Expired - Lifetime
- 2002-08-30 DK DK02757486.2T patent/DK1427750T3/da active
- 2002-08-30 JP JP2003525016A patent/JP2005508623A/ja active Pending
- 2002-08-30 DE DE60238541T patent/DE60238541D1/de not_active Expired - Lifetime
- 2002-08-30 AT AT02757486T patent/ATE490969T1/de not_active IP Right Cessation
- 2002-08-30 US US10/231,494 patent/US20040023334A1/en not_active Abandoned
- 2002-08-30 KR KR10-2004-7002867A patent/KR20040059490A/ko not_active Ceased
- 2002-08-30 CA CA002457520A patent/CA2457520A1/en active Pending
- 2002-08-30 IL IL16028902A patent/IL160289A0/xx unknown
- 2002-08-30 MX MXPA04001804A patent/MXPA04001804A/es active IP Right Grant
- 2002-08-30 AU AU2002323501A patent/AU2002323501C1/en not_active Ceased
- 2002-08-30 WO PCT/US2002/027637 patent/WO2003020746A1/en not_active Ceased
- 2002-08-30 NZ NZ531207A patent/NZ531207A/en not_active IP Right Cessation
-
2004
- 2004-02-10 ZA ZA2004/01079A patent/ZA200401079B/en unknown
-
2009
- 2009-08-27 JP JP2009197098A patent/JP2010004891A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| JP2005508623A (ja) | 2005-04-07 |
| MXPA04001804A (es) | 2005-03-07 |
| US20040023334A1 (en) | 2004-02-05 |
| DK1427750T3 (da) | 2011-02-14 |
| JP2010004891A (ja) | 2010-01-14 |
| DE60238541D1 (de) | 2011-01-20 |
| EP1427750A4 (de) | 2006-01-18 |
| WO2003020746A1 (en) | 2003-03-13 |
| AU2002323501C1 (en) | 2010-04-29 |
| RU2004109222A (ru) | 2005-10-20 |
| EP1427750A1 (de) | 2004-06-16 |
| CN1628126A (zh) | 2005-06-15 |
| CA2457520A1 (en) | 2003-03-13 |
| ZA200401079B (en) | 2005-05-25 |
| IL160289A0 (en) | 2004-07-25 |
| AU2002323501B2 (en) | 2009-03-26 |
| NZ531207A (en) | 2006-08-31 |
| KR20040059490A (ko) | 2004-07-05 |
| BR0212256A (pt) | 2004-08-31 |
| EP1427750B1 (de) | 2010-12-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK1427750T3 (da) | Modificerede transferrin-fusionsproteiner | |
| WO2004020404A3 (en) | Modified transferin-antibody fusion proteins | |
| DE60333306D1 (de) | Modifizierte transferrin-fusionsproteine mit doppelten transferrin-amino- oder carboxy-terminalen domänen | |
| WO2004020405A3 (en) | Modified transferrin fusion proteins | |
| ATE316982T1 (de) | Mehrere zytokin-antikörper komplexen | |
| EP1423510A4 (de) | Antikörperglykosylierungsvarianten mit erhöhter antikörperabhängiger zellulärer zytotoxizität | |
| DK1088084T3 (da) | Erythropoietin analog-humant serumalbumin fusionsprotein | |
| PL369741A1 (en) | Immunocytokines with modulated selectivity | |
| DE50012863D1 (de) | Strukturprotein von adeno-assoziiertem virus mit veränderten chromatographischen eigenschaften | |
| YU9404A (sh) | Multimerna, usmerena kontrastna sredstva na bazi peptida | |
| WO2005021579A3 (en) | Epo mimetic peptides and fusion proteins | |
| EP0724456A4 (de) | Antikörper gegen cd40 | |
| MXPA02004666A (es) | Gelatinas recombinantes. | |
| WO2002079232A3 (en) | Reducing the immunogenicity of fusion proteins | |
| WO2007047504A3 (en) | Natriuretic peptide modified transferrin fusion proteins | |
| DK1539221T3 (da) | Transferrin-fusionsproteinbiblioteker | |
| WO2006049983A3 (en) | Peptide yy modified transferrin fusion proteins | |
| BR0212287A (pt) | Proteìna de ligação caspase-8, sua preparação e uso | |
| WO2001002429A3 (en) | Angiopoietin-6 and uses thereof | |
| BR0315222A (pt) | Promotor de il-18bp, sua preparação e uso | |
| TW200635953A (en) | Specific binding agents of human angiopoietin-2 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |